View in EDS HTML Full Text PDF Full Text

The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan.

Saved in:
Bibliographic Details
Title: The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan.
Authors: Veenit V; Bioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Heerspink HJL; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Ahlström C; DMPK, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Greasley PJ; Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Skritic S; Innovation Strategies & External Liaison, Pharmaceutical Technologies & Development, AstraZeneca, Gothenburg, Sweden; Institute of Medicine at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.; Institute of Medicine at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., van Zuydam N; Biostatistics Sweden, Data Science and Quantitative Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Kohan DE; Division of Nephrology, University of Utah Health, Salt Lake City, UT, USA., Hansen PBL; Bioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Menzies RI; Bioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Source: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association [Nephrol Dial Transplant] 2023 Sep 29; Vol. 38 (10), pp. 2289-2297.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 8706402 Publication Model: Print Cited Medium: Internet ISSN: 1460-2385 (Electronic) Linking ISSN: 09310509 NLM ISO Abbreviation: Nephrol Dial Transplant Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37102226
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Veenit+V%22">Veenit V</searchLink>; Bioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Heerspink+HJL%22">Heerspink HJL</searchLink>; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Ahlström+C%22">Ahlström C</searchLink>; DMPK, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Greasley+PJ%22">Greasley PJ</searchLink>; Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Skritic+S%22">Skritic S</searchLink>; Innovation Strategies & External Liaison, Pharmaceutical Technologies & Development, AstraZeneca, Gothenburg, Sweden; Institute of Medicine at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.; Institute of Medicine at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22van+Zuydam+N%22">van Zuydam N</searchLink>; Biostatistics Sweden, Data Science and Quantitative Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Kohan+DE%22">Kohan DE</searchLink>; Division of Nephrology, University of Utah Health, Salt Lake City, UT, USA.<br /><searchLink fieldCode="AU" term="%22Hansen+PBL%22">Hansen PBL</searchLink>; Bioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Menzies+RI%22">Menzies RI</searchLink>; Bioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228706402%22">Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</searchLink> [Nephrol Dial Transplant] 2023 Sep 29; Vol. 38 (10), pp. 2289-2297.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>8706402 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1460-2385 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209310509%22">09310509 </searchLink><i>NLM ISO Abbreviation: </i>Nephrol Dial Transplant <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37102226
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1093/ndt/gfad078
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2289
    Titles:
      – TitleFull: The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Veenit V
      – PersonEntity:
          Name:
            NameFull: Heerspink HJL
      – PersonEntity:
          Name:
            NameFull: Ahlström C
      – PersonEntity:
          Name:
            NameFull: Greasley PJ
      – PersonEntity:
          Name:
            NameFull: Skritic S
      – PersonEntity:
          Name:
            NameFull: van Zuydam N
      – PersonEntity:
          Name:
            NameFull: Kohan DE
      – PersonEntity:
          Name:
            NameFull: Hansen PBL
      – PersonEntity:
          Name:
            NameFull: Menzies RI
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 29
              M: 09
              Text: 2023 Sep 29
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 1460-2385
          Numbering:
            – Type: volume
              Value: 38
            – Type: issue
              Value: 10
          Titles:
            – TitleFull: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
              Type: main
ResultId 1